What Conditions Are Dezawa Muse Cells Being Studied For?

What conditions can Dezawa Muse cells treat?

This question needs to be framed carefully. Dezawa Muse cells are not approved to treat any condition in the United States. What exists is a body of clinical research - primarily from Japan, where the clinical-grade Muse cell product CL2020 was developed under the Life Science Institute (LSII), a subsidiary of Mitsubishi Chemical Group - that has investigated them across multiple diseases.

The plain framing: Muse cells have been administered to real patients in registered clinical trials, results have been published in peer-reviewed journals, and some of those results are meaningful. They are preliminary. A condition appearing on this list means researchers considered the biology plausible enough to test in humans - not that the therapy is proven, approved, or widely available.

With that context in place, here is what the published literature shows for each condition, organized by the quality and size of the available evidence.

Are Muse cells effective for heart attacks?

The cardiovascular indication was the first to be tested in human subjects and remains one of the most biologically compelling. Muse cells express the sphingosine-1-phosphate receptor 2 (S1PR2), which directs them to accumulate at sites of ischemic injury. In published animal studies, they differentiated into cardiomyocyte-like cells and reduced infarct size without triggering arrhythmias - a known risk with other cell therapies.

The LVEF finding deserves context. A jump from 40.7% to 52.0% is clinically meaningful if it holds - a 45% ejection fraction is associated with significantly increased mortality risk in heart failure, and the normal range begins around 55%. However, three patients without a control group cannot tell us how much of that improvement reflects cell therapy versus natural post-infarct recovery or optimal medical management. Controlled, adequately powered follow-on studies would be needed to answer that question.

An expanded Phase 2 program was under development at LSII before Mitsubishi Chemical Group announced in February 2023 that it was discontinuing the development of CL2020. The cardiovascular indication, while biologically well-supported, has not advanced to a randomized controlled trial.

Can Muse cells help with stroke recovery?

The ischemic stroke trial represents the most methodologically rigorous Muse cell study published to date. It is the only Muse cell trial that was both randomized and placebo-controlled, which means its findings carry more interpretive weight than the open-label studies.

The mRS response rate gap - 40% versus 10% - is notable given the difficult nature of subacute stroke. The mRS measures disability on a 0-6 scale; a score of 2 means a patient can carry out normal activities without assistance despite some symptoms. Moving from mRS ≥3 (requiring assistance for daily activities) to ≤2 is a meaningful functional shift.

Caveats: The study was 35 patients total. The placebo group was only 10 patients. These are promising pilot data, not a definitive demonstration of efficacy. The same study noted that the lower confidence interval of the treatment effect (21.1%) exceeded the prespecified efficacy threshold (8.7%), which the authors interpreted as evidence of potential benefit. A Phase 3 confirmatory trial was the anticipated next step, but LSII's development program was discontinued before that stage.

The biological rationale for stroke is strong. Muse cells migrate toward sphingosine-1-phosphate signals released by ischemic tissue and can differentiate into neuron-like cells and vascular endothelial cells in the infarcted area - both of which are lost in ischemic stroke. No immunosuppressant medication was used in the trial, and no serious treatment-related adverse events were observed.

Are Muse cells used for spinal cord injury?

Spinal cord injury presents one of the most intractable challenges in regenerative medicine. The injury destroys both neurons and the myelin sheaths that insulate them, and the environment around a chronic spinal cord lesion is actively hostile to regeneration. Muse cells' ability to differentiate into both neuron-like and oligodendrocyte-like cells (myelin-producing cells) in published preclinical work motivated a clinical investigation.

Interpreting these results requires care. Six of 10 patients improving at least one Frankel grade is a meaningful signal, but acute spinal cord injuries can show natural neurological recovery in the months following injury - especially in incomplete injuries (Frankel B classification). Without a concurrent control group, it is not possible to determine how much of the observed improvement reflects cell therapy versus natural recovery course.

The study authors acknowledged this limitation and concluded that the data establish safety and feasibility, supporting the rationale for a controlled Phase 2 study. As of the most recent published data, no such controlled trial has been completed.

What about Muse cells for epidermolysis bullosa?

Epidermolysis bullosa (EB) is a rare genetic disorder in which mutations in structural proteins cause the skin to blister and tear with minimal trauma. Severe forms result in chronic open wounds, scarring, and significant pain throughout life. There is no approved cure, and management is largely wound care and pain control.

The rationale for Muse cell therapy in EB draws on their capacity to differentiate into skin-relevant cell types, including keratinocyte-like cells and fibroblast-like cells, in response to the damaged tissue environment. The systemic intravenous route offers a path to reaching widespread skin involvement without requiring direct wound injection at every site.

Five patients is a very small number. The EB trial does not answer whether Muse cells are an effective treatment for this condition - it answers whether the procedure is safe enough to continue studying. The wound reduction findings in two patients are encouraging signals, but EB wound burden also fluctuates with infection, nutritional status, and care protocols, making interpretation without controls difficult.

For a condition this rare and this under-served, even preliminary safety data with a signal of biological activity is meaningful for the research community.

Are Muse cells effective for ALS?

Amyotrophic lateral sclerosis is a progressive neurodegenerative disease that destroys motor neurons. It has no approved cure, and most approved treatments slow progression modestly. The biological rationale for Muse cells in ALS centers on their capacity to differentiate into motor neuron-like cells in preclinical models and their ability to home toward sites of neuronal injury.

The ALS results are the most mixed in the Muse cell portfolio. The safety data is credible - repeated dosing without HLA matching, without immunosuppressants, and without serious adverse events across 5 patients is consistent with Muse cells' immune-privileged profile. But the efficacy signal is weak. ALS progresses differently in each patient, and a five-person open-label study cannot distinguish a treatment effect from natural variation.

The discontinuation of CL2020 development by Mitsubishi in 2023 means there will be no commercially sponsored Phase 3 data for ALS in the near term. Academic research on Muse cells in neurodegeneration continues.

Are Muse cells effective for ARDS or lung injury?

Acute respiratory distress syndrome (ARDS) is a severe inflammatory lung condition with high mortality, often triggered by sepsis, pneumonia, or - during 2020 to 2022 - COVID-19. Cell therapies have been studied as potential modulators of the cytokine storm and lung injury associated with ARDS, based on the immunomodulatory properties of mesenchymal-lineage cells.

For Muse cells specifically, published preclinical data shows that intravenously administered Muse cells home to injured lung tissue and can differentiate into alveolar epithelial-like cells in animal models. Their immunomodulatory properties - including the expression of anti-inflammatory markers and the ability to reduce cytokine levels in damaged tissue - provide a biological basis for investigating them in ARDS.

A small exploratory clinical study was conducted in Japan during the COVID-19 pandemic administering CL2020 to patients with severe ARDS. Early observations suggested potential reductions in lung inflammation, but detailed results were not published in a peer-reviewed journal as of 2026. This indication is listed in the LSII CL2020 program as an area of investigation, but should be considered the least evidenced of the conditions covered in this article.

For context on what the broader ARDS stem cell literature shows: a randomized, controlled Phase 2 trial of mesenchymal stromal cells (not Muse cells specifically) in COVID-19 ARDS, published in the New England Journal of Medicine Evidence, enrolled 222 patients and did not find a statistically significant reduction in 30-day mortality. This underscores how difficult the ARDS indication is across all cell therapy approaches.

What other conditions have been investigated?

Neonatal hypoxic-ischemic encephalopathy

Hypoxic-ischemic encephalopathy (HIE) occurs when a newborn's brain is deprived of oxygen during or around birth. It is a leading cause of cerebral palsy and neurodevelopmental disability. The standard of care, therapeutic hypothermia (cooling), reduces injury but does not eliminate it.

The SHIELD trial is notable for its patient population: neonates, where safety standards are especially stringent. The favorable developmental outcomes at 18 months are encouraging, but the trial explicitly acknowledges that with only 9 patients and no control group, a randomized confirmatory study is needed to separate cell therapy effects from the benefit of therapeutic hypothermia alone.

Orthopedic and joint conditions

Cartilage degeneration, osteoarthritis, bone non-unions, and tendon injuries represent a large potential application area based on preclinical data. Muse cells can differentiate into chondrogenic (cartilage-forming) and osteogenic (bone-forming) cell types in published laboratory studies. As of 2026, no peer-reviewed clinical trial results for Muse cells in orthopedic conditions have been published. This is an area of active preclinical interest.

Organ conditions: liver and kidney

Because Muse cells can differentiate into endoderm-derived tissues - including hepatocyte-like (liver) cells and renal tubular-like cells in preclinical models - researchers have investigated their potential in liver cirrhosis and kidney injury animal models. Published preclinical results show structural tissue integration and functional improvement in animal studies. No clinical trial data in humans has been published for these indications as of 2026.

What conditions have the strongest clinical evidence?

Ranking by the quality of the human evidence available:

1. Ischemic stroke - The only Muse cell trial with a randomized, double-blind, placebo-controlled design. Thirty-five patients. Published response rate advantage (40% vs. 10% at 12 weeks). This is the strongest human evidence for any Muse cell indication.
2. Spinal cord injury - Phase 1/2a with 10 patients, statistically significant motor improvement across multiple timepoints, published in 2024. The absence of a control group limits causal conclusions.
3. Epidermolysis bullosa - Five patients, published wound reduction signal, no control group. Important as safety evidence for a condition with few options.
4. Acute myocardial infarction - Three patients, compelling LVEF improvement from 40.7% to 52.0%, no control group. Strong preclinical data supports the biological rationale.
5. ALS - Five patients, stabilization signal in ALSFRS-R, no control group. Development discontinued in 2023.
6. Neonatal HIE (SHIELD) - Nine neonates, favorable 18-month developmental outcomes, no control group. Exploratory safety study.
7. COVID-19 ARDS - Limited published data. Listed in the LSII program, minimal peer-reviewed results available.

An important context for all of these findings: the Muse cell-specific clinical evidence base is considerably more limited in scale than the general mesenchymal stem cell literature, which includes meta-analyses covering thousands of patients across dozens of randomized controlled trials. Muse cells are biologically distinct from standard MSCs, but they are earlier in their clinical development trajectory. The mechanism is well-characterized in peer-reviewed literature. The efficacy evidence in humans is preliminary across all indications.

Why did Mitsubishi discontinue CL2020 development?

In February 2023, Mitsubishi Chemical Group announced it would discontinue development of CL2020 across all indications. This was a commercial and strategic decision by the parent company - it does not mean the science was disproven. The Phase 2 stroke trial data was published in September 2023, after the discontinuation announcement, and its authors described the results as evidence of potential clinical benefit warranting further investigation.

The CL2020 development program produced a body of peer-reviewed safety and preliminary efficacy data across seven conditions. That data exists in the literature regardless of LSII's commercial decisions. Academic researchers and other companies hold licenses to Muse cell intellectual property. The Dezawa laboratory at Tohoku University remains active. MuseCell Innovations continues to develop the technology commercially.

Where can I find ongoing Muse cell clinical trials?

U.S.-registered studies can be found at ClinicalTrials.gov by searching "Muse cells." The SHIELD trial for neonatal HIE carries the identifier NCT04261335. Japanese trials not registered on ClinicalTrials.gov may appear in the Japan Registry of Clinical Trials (jRCT) at jrct.niph.go.jp; the spinal cord injury trial carries the identifier JRCT1080224764, and the SHIELD trial additionally carries jRCT2043190112.

For the stroke, cardiac, and EB trials, the registration identifiers are in the JapicCTI system (Japan Pharmaceutical Information Center Clinical Trials Information): JapicCTI-184103 for stroke and JapicCTI-183834 for the first cardiac study. These may be searchable at clinicaltrials.jp.